DK3826667T3 - Claudin6-antistoffer og fremgangsmåder til behandling af kræft - Google Patents
Claudin6-antistoffer og fremgangsmåder til behandling af kræft Download PDFInfo
- Publication number
- DK3826667T3 DK3826667T3 DK18857242.4T DK18857242T DK3826667T3 DK 3826667 T3 DK3826667 T3 DK 3826667T3 DK 18857242 T DK18857242 T DK 18857242T DK 3826667 T3 DK3826667 T3 DK 3826667T3
- Authority
- DK
- Denmark
- Prior art keywords
- claudin6
- antibodies
- cancer
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560143P | 2017-09-18 | 2017-09-18 | |
| PCT/US2018/051610 WO2019056023A2 (en) | 2017-09-18 | 2018-09-18 | ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3826667T3 true DK3826667T3 (da) | 2024-07-22 |
Family
ID=65723110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18857242.4T DK3826667T3 (da) | 2017-09-18 | 2018-09-18 | Claudin6-antistoffer og fremgangsmåder til behandling af kræft |
Country Status (22)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002921A (es) * | 2017-09-18 | 2020-09-28 | Univ California | Anticuerpos para claudin6 y métodos para tratar el cáncer. |
| IL273471B2 (en) | 2017-09-29 | 2023-09-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a pyrrolobenzodiazepine derivative |
| KR102063341B1 (ko) * | 2018-12-31 | 2020-01-07 | 다이노나(주) | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 |
| SG11202108281UA (en) | 2019-02-15 | 2021-08-30 | Integral Molecular Inc | Claudin 6 antibodies and uses thereof |
| JP7682797B2 (ja) * | 2019-03-20 | 2025-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン６二重特異性抗体 |
| JP7682798B2 (ja) * | 2019-03-20 | 2025-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン６抗体及び薬物複合体 |
| JP2023529557A (ja) | 2020-05-04 | 2023-07-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗ｅｎｐｐ１抗体の阻害 |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| US20250042996A1 (en) * | 2021-11-16 | 2025-02-06 | Christopher Bebbington | Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9 |
| JP2025508362A (ja) * | 2022-02-09 | 2025-03-26 | セラ プログノスティックス， インコーポレイテッド | Ｓｈｂｇおよびｉｂｐ４抗体、ならびにそれを使用する方法 |
| CN120282987A (zh) | 2022-11-30 | 2025-07-08 | 因特格尔莫来库乐有限公司 | 包括双特异性型式的针对紧密连接蛋白6的抗体 |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
| WO2025075127A1 (ja) * | 2023-10-04 | 2025-04-10 | 公立大学法人福島県立医科大学 | がんのバイオマーカー及び抗体治療 |
| WO2025146161A1 (en) * | 2024-01-04 | 2025-07-10 | Hansoh Bio Llc | Antibody, antigen-binding fragment and medical use thereof |
| WO2025162270A1 (zh) * | 2024-02-01 | 2025-08-07 | 江苏恒瑞医药股份有限公司 | 抗cldn6抗体、其抗体-药物偶联物及其医药用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| ATE92499T1 (de) | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| US6303144B1 (en) | 1998-02-10 | 2001-10-16 | Welfide Corporation | Preparations with controlled release |
| JP2003530297A (ja) | 1998-10-16 | 2003-10-14 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｖｉｐアンタゴニストを用いる併用療法 |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| JP2005512044A (ja) | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | 結合特性に基づく抗体分類 |
| US7917208B2 (en) | 2002-10-04 | 2011-03-29 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| JP5632582B2 (ja) * | 2006-12-14 | 2014-11-26 | 中外製薬株式会社 | 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断 |
| EP2139458A4 (en) | 2007-04-19 | 2013-01-23 | Dong A Pharm Co Ltd | COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA |
| EP3064512B1 (en) * | 2008-01-11 | 2023-08-30 | The University of Tokyo | Anti-cldn6 antibody |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| DK2707390T3 (en) * | 2011-05-13 | 2016-02-29 | Ganymed Pharmaceuticals Ag | ANTIBODIES TO TREAT CANCER EXPRESSING CLAUDIN 6 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| BR112016010169A2 (pt) * | 2013-11-06 | 2017-12-05 | Stemcentrx Inc | anticorpos anticlaudina e métodos de uso |
| CA2942459C (en) * | 2014-04-01 | 2023-03-07 | Biontech Cell & Gene Therapies Gmbh | Claudin-6-specific immunoreceptors and t cell epitopes |
| MX2020002921A (es) * | 2017-09-18 | 2020-09-28 | Univ California | Anticuerpos para claudin6 y métodos para tratar el cáncer. |
-
2018
- 2018-09-18 MX MX2020002921A patent/MX2020002921A/es unknown
- 2018-09-18 SG SG11202002114RA patent/SG11202002114RA/en unknown
- 2018-09-18 WO PCT/US2018/051610 patent/WO2019056023A2/en not_active Ceased
- 2018-09-18 EP EP24169481.9A patent/EP4435009A3/en active Pending
- 2018-09-18 AU AU2018334434A patent/AU2018334434B2/en active Active
- 2018-09-18 BR BR112020005196-9A patent/BR112020005196A2/pt unknown
- 2018-09-18 GB GBGB2103867.4A patent/GB202103867D0/en active Pending
- 2018-09-18 PT PT188572424T patent/PT3826667T/pt unknown
- 2018-09-18 KR KR1020207009742A patent/KR102793719B1/ko active Active
- 2018-09-18 SI SI201831128T patent/SI3826667T1/sl unknown
- 2018-09-18 IL IL273196A patent/IL273196B2/en unknown
- 2018-09-18 US US16/648,428 patent/US20200291111A1/en not_active Abandoned
- 2018-09-18 IL IL313238A patent/IL313238A/en unknown
- 2018-09-18 FI FIEP18857242.4T patent/FI3826667T3/fi active
- 2018-09-18 CN CN202410853420.8A patent/CN118667021A/zh active Pending
- 2018-09-18 EP EP18857242.4A patent/EP3826667B1/en active Active
- 2018-09-18 ES ES18857242T patent/ES2986343T3/es active Active
- 2018-09-18 NO NO20210351A patent/NO20210351A1/en not_active Application Discontinuation
- 2018-09-18 DK DK18857242.4T patent/DK3826667T3/da active
- 2018-09-18 CN CN201880073220.3A patent/CN111565744B/zh active Active
- 2018-09-18 CA CA3076207A patent/CA3076207A1/en active Pending
- 2018-09-18 JP JP2020515692A patent/JP7599332B2/ja active Active
- 2018-09-18 PL PL18857242.4T patent/PL3826667T3/pl unknown
- 2018-09-18 KR KR1020257011014A patent/KR20250050137A/ko active Pending
- 2018-09-18 HU HUE18857242A patent/HUE067603T2/hu unknown
-
2020
- 2020-03-17 MX MX2025012685A patent/MX2025012685A/es unknown
-
2021
- 2021-03-19 CZ CZ2021138A patent/CZ2021138A3/cs unknown
-
2022
- 2022-04-13 US US17/719,609 patent/US20220372134A1/en not_active Abandoned
-
2023
- 2023-12-19 US US18/545,890 patent/US20240400674A1/en not_active Abandoned
-
2024
- 2024-06-20 JP JP2024099523A patent/JP2024150445A/ja active Pending
-
2025
- 2025-01-23 AU AU2025200467A patent/AU2025200467A1/en active Pending
- 2025-06-27 US US19/252,512 patent/US20250333501A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3826667T3 (da) | Claudin6-antistoffer og fremgangsmåder til behandling af kræft | |
| DK3455259T3 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
| DK3601358T5 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3551660T5 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3565844T5 (da) | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
| DK3295951T3 (da) | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse | |
| DK3310812T3 (da) | Anti-HER2-antistoffer og fremgangsmåder til anvendelse | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3303386T3 (da) | Anti-Tau-antistoffer og fremgangsmåder til anvendlelse | |
| DK3356404T3 (da) | Anti-pd1-antistoffer og fremgangsmåder til anvendelse | |
| DK3292149T3 (da) | Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3250610T3 (da) | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf | |
| DK3126394T3 (da) | Anti-OX40-antistoffer og fremgangsmåder til anvendelse | |
| DK3491025T3 (da) | Fcrn-antistoffer og anvendelsesmetoder heraf | |
| DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| DK3148579T3 (da) | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3280440T3 (da) | Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3474996T3 (da) | Tågeapparat og anvendelsesmåde | |
| DK3390442T5 (da) | Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf | |
| DK3426777T3 (da) | Kombinationsvektorer og fremgangsmåder til behandling af cancer |